In 2014 the Company entered into a license agreement with Merck to develop, manufacture and commercialize NewLink Genetics’ Ebola vaccine candidate AMES, Iowa, Nov. 15, 2018 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (NASDAQ:NLNK) reported today that...